Opinion

Video

Fruquintinib in mCRC: Key Insights From FRESCO-2

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Video content above is prompted by the following:

  1. New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
  2. Include in this discussion that all patients previously received regorafenib or FTD/TPI.
  3. What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?
Related Videos
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Raj Chovatiya, MD, PhD, MSCI.
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
4 experts are featured in this series.
Related Content
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser
Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
"Overactive bladder" written on sticky note | Image Credit: syahrir - stock.adobe.com
April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick
Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick
The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo